WEBINAR: Hepatitis C Treatment in People with Substance Use Disorder
Starts at: October 23, 2019 12:00pm ET
Ends at: October 23, 2019 1:00pm ET
The purpose of this webinar is to enable participants to increase their knowledge regarding Hepatitis C Treatment in People with Substance Use Disorder.
Upon completion, participants will be able to:
1. Describe the common barriers associated with hepatitis C treatment in People with Substance Use Disorder
2. Discuss the application of harm reduction principles to increase success in treating HCV infection in people who have substance use disorder
Stacey Trooskin, MD, PhD, MPH Director of Viral Hepatitis Programs, Philadelphia FIGHT Community Health Centers Clinical Assistant Professor of Medicine, Perelman School of Medicine, University of Pennsylvania
PSNA: The MidAtlantic AIDS Education and Training Center is an approved provider of continuing education by the Pennsylvania State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. This activity qualifies for 1.0 contact hours.
CME: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Pittsburgh School of Medicine and MidAtlantic AIDS Education and Training Center. The University of Pittsburgh School of Medicine accredited by the ACCME to provide continuing medical education for physicians.
The University of Pittsburgh School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other health care profesionals are awarded 0.1 continuing education units (CEU's) which are equal to 1.0 contact hours.
CEU: The MidAtlantic AIDS Education and Training Center, Department of Infectious Diseases and Microbiology, University of Pittsburgh, awards Continuing Education Units to individuals who enroll in certain educational activities. This program is awarded 0.10 continuing education credits.
Planners have no conflicts of interest relative to this educational activity.
Speaker disclosures - Dr. Trooskin has a Gilead Sciences grant and is on a Gilead Sciences Advisory board.
A variety of the listed topics will be discussed at this event.